Circulating soluble CD30 levels in primary Sjögren's syndrome, SLE and rheumatoid arthritis.

Y Ichikawa, Makie Yoshida, C Yamada, Terumi Horiki, Yuichi Hoshina, M Uchiyama

Clinical and Experimental Rheumatology · 1999 · 12 citations · 0 references

Abstract

The treatment of modifiable risk factors can have a preventive effects on cognitive decline and dementia. More research is needed to identify subgroups with the greatest likelihood of benefits.